Estudos computacionais para novas possibilidades de síntese de moléculas candidatas a fármacos
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora - Campus Avançado de Governador Valadares
DOI
Abstract
The discovery of new drugs is a challenging field involving multiple stages of testing and
regulatory approval. However, it holds the potential to transform disease treatment, improve
patients’ quality of life, and even save lives. Bioinformatics plays a fundamental role in drug
development, enabling a more efficient and precise approach to the discovery and
optimization of new therapeutic agents. Virtual screening, for instance, employs
computational simulations to identify the most promising molecules for specific targets.
This allows for a faster and more targeted selection of potential drug candidates, reducing
the number of compounds that need to be experimentally tested. After the identification and
validation of a pharmacological target—such as kinase enzymes in cancer—it becomes
possible to design promising molecules for that target. In the case of brain cancers, such as
glioblastoma, studies focused on the ability of molecules to cross the blood–brain barrier can
contribute significantly. In this context, previous computational studies were carried out to
select molecules with favorable pharmacokinetic parameters, high biological activity, and
feasible synthetic potential. The objective of this work was to perform in silico studies to
select promising molecules that could be proposed as new potential drug candidates for
glioblastoma treatment. An in silico study involving 57 molecules was conducted. All
proposed molecules were evaluated using computational platforms to assess
pharmacokinetic parameters such as oral bioavailability according to Lipinski’s “Rule of
Five,” kinase inhibition potential, and ability to cross the blood–brain barrier. In this study, it
was possible to identify a group of the most promising molecules. Molecules 20, 39, 44, 45,
51, and 55 demonstrated potential to cross the blood–brain barrier, according to the final
Score defined in this study. Molecules 20, 39, 45, 51, 54, 55, 56, and 57 showed promising
kinase inhibition activity based on their calculated pIC50 values, indicating them as the most
promising candidates. Notably, molecule 39 stood out by presenting the highest estimated
pIC50 value and the highest overall Score in the screening. Therefore, through this in silico
study, molecule 39 can be highlighted as the most promising candidate for synthesis and in
vitro testing.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

